What was keytruda's first fda approved cancer indication?

What was Keytruda’s first FDA-approved cancer indication?

Keytruda (pembrolizumab) received its first FDA approval for unresectable or metastatic melanoma—specifically, patients whose melanoma had progressed after ipilimumab and, if it was BRAF V600 mutation–positive, after a BRAF inhibitor. [1]

When did that approval happen?

That initial FDA approval was granted in 2014. [1]

Sources:
[1] https://www.drugs.com/new-drug-approval/Keytruda-pembrolizumab-2014.html